Blog
NeuroAiD™II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression
SINGAPORE, January 22 Moleac is pleased to announce the release of the ATHENE study results, published in the Journal of the American Medical Director Association (JAMDA)¹. Alzheimer’s Disease (AD) and other dementias cause a heavy economic and public healthcare...
Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals
SINGAPORE, MAY 2021 Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals. Moleac is dedicated in finding, developing, and commercializing new medicines for the unmet medical needs of patients suffering from...
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery
SINGAPORE, APRIL 21 Moleac, a biopharmaceutical company based in Singapore, announced the approval by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for MLC1501 in traumatic brain injury (TBI). Moleac is dedicated in...
